Abstract
Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is presented. Despite treatment with ursodeoxycholic acid and cholestyramine, bilirubin and transaminase levels remained elevated. This case report raises awareness of the difficulty of managing this condition in patients with COVID-19.
| Original language | English (US) |
|---|---|
| Article number | 100116 |
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | Journal of Translational Autoimmunity |
| Volume | 4 |
| Early online date | Aug 31 2021 |
| DOIs | |
| State | Published - 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Cholangiopathy as part of post-COVID syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver